Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/THADA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/THADA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/THADA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/THADA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00324698 | Cervix | CC | endoplasmic reticulum calcium ion homeostasis | 10/2311 | 25/18723 | 4.52e-04 | 4.49e-03 | 10 |
GO:00324699 | Endometrium | AEH | endoplasmic reticulum calcium ion homeostasis | 11/2100 | 25/18723 | 3.42e-05 | 6.06e-04 | 11 |
GO:00510515 | Endometrium | AEH | negative regulation of transport | 79/2100 | 470/18723 | 1.51e-04 | 1.99e-03 | 79 |
GO:00109597 | Endometrium | AEH | regulation of metal ion transport | 66/2100 | 406/18723 | 1.24e-03 | 1.07e-02 | 66 |
GO:00344707 | Endometrium | AEH | ncRNA processing | 62/2100 | 395/18723 | 3.93e-03 | 2.65e-02 | 62 |
GO:0034766 | Endometrium | AEH | negative regulation of ion transmembrane transport | 22/2100 | 109/18723 | 4.39e-03 | 2.89e-02 | 22 |
GO:0043271 | Endometrium | AEH | negative regulation of ion transport | 29/2100 | 160/18723 | 6.16e-03 | 3.70e-02 | 29 |
GO:00228986 | Endometrium | AEH | regulation of transmembrane transporter activity | 45/2100 | 278/18723 | 7.34e-03 | 4.18e-02 | 45 |
GO:0034763 | Endometrium | AEH | negative regulation of transmembrane transport | 26/2100 | 143/18723 | 8.78e-03 | 4.78e-02 | 26 |
GO:1904063 | Endometrium | AEH | negative regulation of cation transmembrane transport | 20/2100 | 102/18723 | 8.88e-03 | 4.82e-02 | 20 |
GO:19040623 | Endometrium | AEH | regulation of cation transmembrane transport | 55/2100 | 357/18723 | 9.18e-03 | 4.96e-02 | 55 |
GO:003246915 | Endometrium | EEC | endoplasmic reticulum calcium ion homeostasis | 12/2168 | 25/18723 | 6.86e-06 | 1.61e-04 | 12 |
GO:005105111 | Endometrium | EEC | negative regulation of transport | 80/2168 | 470/18723 | 2.53e-04 | 2.93e-03 | 80 |
GO:001095914 | Endometrium | EEC | regulation of metal ion transport | 70/2168 | 406/18723 | 4.12e-04 | 4.35e-03 | 70 |
GO:003447012 | Endometrium | EEC | ncRNA processing | 63/2168 | 395/18723 | 5.20e-03 | 3.26e-02 | 63 |
GO:00347661 | Endometrium | EEC | negative regulation of ion transmembrane transport | 22/2168 | 109/18723 | 6.39e-03 | 3.76e-02 | 22 |
GO:00550883 | Liver | NAFLD | lipid homeostasis | 44/1882 | 167/18723 | 1.48e-09 | 2.54e-07 | 44 |
GO:19908452 | Liver | NAFLD | adaptive thermogenesis | 28/1882 | 157/18723 | 1.91e-03 | 1.93e-02 | 28 |
GO:00344704 | Liver | NAFLD | ncRNA processing | 57/1882 | 395/18723 | 3.34e-03 | 2.93e-02 | 57 |
GO:0043414 | Liver | NAFLD | macromolecule methylation | 47/1882 | 316/18723 | 4.08e-03 | 3.41e-02 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THADA | SNV | Missense_Mutation | rs763566405 | c.3662C>T | p.Thr1221Met | p.T1221M | Q6YHU6 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THADA | SNV | Missense_Mutation | novel | c.5324N>T | p.Ser1775Phe | p.S1775F | Q6YHU6 | protein_coding | deleterious(0.01) | possibly_damaging(0.726) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
THADA | SNV | Missense_Mutation | novel | c.3961N>C | p.Phe1321Leu | p.F1321L | Q6YHU6 | protein_coding | deleterious(0) | benign(0.368) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
THADA | SNV | Missense_Mutation | rs766364697 | c.3599N>G | p.Asp1200Gly | p.D1200G | Q6YHU6 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
THADA | SNV | Missense_Mutation | rs138949612 | c.1949G>A | p.Arg650Gln | p.R650Q | Q6YHU6 | protein_coding | deleterious(0.01) | probably_damaging(0.92) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
THADA | SNV | Missense_Mutation | novel | c.1702C>A | p.Leu568Ile | p.L568I | Q6YHU6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
THADA | SNV | Missense_Mutation | rs753930206 | c.5822C>T | p.Ser1941Leu | p.S1941L | Q6YHU6 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
THADA | SNV | Missense_Mutation | | c.4234N>A | p.His1412Asn | p.H1412N | Q6YHU6 | protein_coding | tolerated(0.11) | benign(0.107) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
THADA | SNV | Missense_Mutation | | c.3024N>C | p.Lys1008Asn | p.K1008N | Q6YHU6 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
THADA | SNV | Missense_Mutation | | c.110N>A | p.Ser37Tyr | p.S37Y | Q6YHU6 | protein_coding | deleterious(0.02) | possibly_damaging(0.87) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |